Valneva SE | Mid-cap | Healthcare
€5.05
2.42%
| Valneva SE Stock Comparison:
Valneva SE vs Abivax SAValneva SE vs Medincell S.AValneva SE vs Inventiva S.AValneva SE vs BNP Paribas EasyValneva SE vs NanobiotixValneva SE vs CAC 40 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 49.2M
Gross Profit 26.2M 53.20%
Operating Income -6.0M -12.11%
Net Income -9.2M -18.75%
EPS (Diluted) €-0.06

Balance Sheet Metrics

Total Assets 482.2M
Total Liabilities 307.0M
Shareholders Equity 175.3M
Debt to Equity 1.75

Cash Flow Metrics

Operating Cash Flow -7.7M
Free Cash Flow -9.6M

Revenue & Profitability Trend

Valneva SE Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i169.6M153.7M361.3M348.1M110.3M
Cost of Goods Sold i98.5M100.9M324.4M187.9M54.3M
Gross Profit i71.0M52.8M36.9M160.2M56.0M
Gross Margin % i41.9%34.4%10.2%46.0%50.8%
Operating Expenses
Research & Development i74.1M59.9M104.9M173.3M84.5M
Selling, General & Administrative i95.1M96.6M57.6M71.2M45.8M
Other Operating Expenses i-20.8M-22.0M-12.5M-23.2M-19.1M
Total Operating Expenses i148.5M134.5M150.0M221.3M111.1M
Operating Income i-77.8M-82.1M-113.4M-61.3M-55.1M
Operating Margin % i-45.9%-53.4%-31.4%-17.6%-50.0%
Non-Operating Items
Interest Income i2.4M1.2M260.0K249.0K119.0K
Interest Expense i24.0M23.3M19.1M17.0M10.7M
Other Non-Operating Income87.9M5.6M-12.6M8.1M437.0K
Pre-tax Income i-11.5M-98.6M-144.8M-70.0M-65.3M
Income Tax i761.0K2.8M-1.5M3.4M-909.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-12.2M-101.4M-143.3M-73.4M-64.4M
Net Margin % i-7.2%-66.0%-39.7%-21.1%-58.4%
Key Metrics
EBITDA i35.0M-63.3M-92.1M-46.8M-45.3M
EPS (Basic) i€-0.08€-0.73€-1.24€-0.75€-0.71
EPS (Diluted) i€-0.08€-0.73€-1.24€-0.75€-0.71
Basic Shares Outstanding i1457058761389438361155475819761932090757173
Diluted Shares Outstanding i1457058761389438361155475819761932090757173

Income Statement Trend

Valneva SE Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i168.3M126.1M286.5M346.6M204.4M
Short-term Investments i-----
Accounts Receivable i35.2M41.6M23.9M44.0M19.2M
Inventory i53.7M44.5M35.1M124.1M26.9M
Other Current Assets41.9M50.6M74.1M71.0M57.8M
Total Current Assets i299.0M262.8M424.7M585.8M308.4M
Non-Current Assets
Property, Plant & Equipment i74.7M136.4M112.7M44.4M29.0M
Goodwill i25.3M25.6M28.7M32.7M35.4M
Intangible Assets i25.3M25.6M28.7M32.7M35.4M
Long-term Investments-----
Other Non-Current Assets17.6M15.1M13.9M22.9M25.0M
Total Non-Current Assets i201.0M197.2M196.7M231.5M140.7M
Total Assets i500.0M460.1M621.3M817.4M449.2M
Liabilities
Current Liabilities
Accounts Payable i12.6M17.6M14.5M16.0M24.9M
Short-term Debt i23.4M47.0M37.0M10.2M9.7M
Current Portion of Long-term Debt-----
Other Current Liabilities5.2M592.0K5.5M5.0M2.8M
Total Current Liabilities i114.6M158.9M277.4M369.0M175.9M
Non-Current Liabilities
Long-term Debt i193.0M161.9M115.4M104.4M95.8M
Deferred Tax Liabilities i4.2M3.6M694.0K1.3M412.0K
Other Non-Current Liabilities48.0K79.0K115.0K70.0K70.0K
Total Non-Current Liabilities i204.2M173.0M124.2M277.8M195.9M
Total Liabilities i318.8M331.8M401.5M646.8M371.7M
Equity
Common Stock i24.4M20.8M20.8M15.8M13.6M
Retained Earnings i-563.9M-551.7M-450.3M-307.0M-233.5M
Treasury Stock i645.0K645.0K645.0K--
Other Equity-----
Total Shareholders Equity i181.3M128.2M219.8M170.6M77.4M
Key Metrics
Total Debt i216.3M208.8M152.4M114.7M105.5M
Working Capital i184.4M104.0M147.3M216.9M132.6M

Balance Sheet Composition

Valneva SE Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-12.2M-101.4M-143.3M-73.4M-64.4M
Depreciation & Amortization i19.6M17.6M21.0M14.3M9.8M
Stock-Based Compensation i8.0M5.1M-8.7M14.5M6.3M
Working Capital Changes i-8.3M-127.7M-131.9M60.2M68.9M
Operating Cash Flow i30.3M-182.3M-231.5M24.2M123.3M
Investing Activities
Capital Expenditures i-13.7M-14.1M-29.2M-92.2M-18.9M
Acquisitions i0-11.0M00-
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i77.1M-21.7M-29.2M-92.2M-18.9M
Financing Activities
Share Repurchases i--240.0K---
Dividends Paid i00000
Debt Issuance i-81.1M39.3M859.0K50.3M
Debt Repayment i-6.5M-5.2M-4.8M-4.8M-24.1M
Financing Cash Flow i-6.5M75.6M224.3M162.9M26.5M
Free Cash Flow i-83.7M-217.1M-274.7M-16.3M118.3M
Net Change in Cash i101.0M-128.4M-36.4M94.9M130.8M

Cash Flow Trend

Valneva SE Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 70.64
Forward P/E -13.62
Price to Book 4.50
Price to Sales 4.37
PEG Ratio -13.62

Profitability Ratios

Profit Margin -34.15%
Operating Margin -22.01%
Return on Equity -38.02%
Return on Assets -6.58%

Financial Health

Current Ratio 2.27
Debt to Equity 105.63
Beta 1.00

Per Share Data

EPS (TTM) €-0.46
Book Value per Share €1.12
Revenue per Share €1.24

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
vla857.1M70.644.50-38.02%-34.15%105.63
Abivax SA 5.0B-23.91-639.37-196.12%0.00%-16.16
Medincell S.A 584.8M--112.65%-66.50%-4.11
Inventiva S.A 536.1M-1.25-1.40172.73%0.00%-1.70
BNP Paribas Easy 463.1M15.99--96.39%-27.22%2.22
Nanobiotix 360.4M-5.10-103.70%0.00%-0.77

Financial data is updated regularly. All figures are in the company's reporting currency.